FI973437A - Soluimmuniteetin uudelleenkohdistus reseptorikimeerien avulla - Google Patents
Soluimmuniteetin uudelleenkohdistus reseptorikimeerien avulla Download PDFInfo
- Publication number
- FI973437A FI973437A FI973437A FI973437A FI973437A FI 973437 A FI973437 A FI 973437A FI 973437 A FI973437 A FI 973437A FI 973437 A FI973437 A FI 973437A FI 973437 A FI973437 A FI 973437A
- Authority
- FI
- Finland
- Prior art keywords
- cell
- infective agent
- chimeric receptors
- target
- receptor
- Prior art date
Links
- 230000007969 cellular immunity Effects 0.000 title 1
- 108700010039 chimeric receptor Proteins 0.000 abstract 6
- 230000001524 infective effect Effects 0.000 abstract 5
- 241000124008 Mammalia Species 0.000 abstract 2
- 230000003834 intracellular effect Effects 0.000 abstract 2
- 108020003175 receptors Proteins 0.000 abstract 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 abstract 1
- 230000036755 cellular response Effects 0.000 abstract 1
- 230000006378 damage Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000011664 signaling Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70514—CD4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/023—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a poxvirus
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39417695A | 1995-02-24 | 1995-02-24 | |
| US39417695 | 1995-02-24 | ||
| PCT/US1996/001056 WO1996025953A1 (en) | 1995-02-24 | 1996-01-25 | Redirection of cellular immunity by receptor chimeras |
| US9601056 | 1996-01-25 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| FI973437A0 FI973437A0 (fi) | 1997-08-21 |
| FI973437A true FI973437A (fi) | 1997-10-16 |
| FI119757B FI119757B (fi) | 2009-03-13 |
Family
ID=23557882
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI973437A FI119757B (fi) | 1995-02-24 | 1997-08-21 | Solut, jotka ilmentävät kimeeristen reseptorien yhdistelmää, ja niiden käyttö terapiassa |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP0871495B1 (fi) |
| JP (1) | JP4170390B2 (fi) |
| KR (1) | KR100490099B1 (fi) |
| AT (1) | ATE297986T1 (fi) |
| AU (1) | AU708339B2 (fi) |
| CA (1) | CA2209300C (fi) |
| CZ (1) | CZ295428B6 (fi) |
| DE (1) | DE69634855T2 (fi) |
| DK (1) | DK0871495T3 (fi) |
| ES (1) | ES2245456T3 (fi) |
| FI (1) | FI119757B (fi) |
| HU (1) | HU225688B1 (fi) |
| NO (1) | NO323632B1 (fi) |
| NZ (2) | NZ337002A (fi) |
| PT (1) | PT871495E (fi) |
| RU (1) | RU2167676C2 (fi) |
| WO (1) | WO1996025953A1 (fi) |
| ZA (1) | ZA961477B (fi) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998017323A1 (en) * | 1996-10-23 | 1998-04-30 | The Trustees Of The University Of Pennsylvania | Improved vaccines |
| AU6692298A (en) * | 1997-03-07 | 1998-09-22 | Ariad Gene Therapeutics, Inc. | New applications of gene therapy technology |
| ES2329741T3 (es) * | 1998-09-23 | 2009-11-30 | Zymogenetics, Inc. | Receptor de citoquinas zalpha11. |
| GB9908807D0 (en) * | 1999-04-16 | 1999-06-09 | Celltech Therapeutics Ltd | Synthetic signalling molecules |
| IL137419A0 (en) * | 2000-07-20 | 2001-07-24 | Yissum Res Dev Co | Nk cells activating receptors and their therapeutic and diagnostic uses |
| WO2006036445A2 (en) | 2004-09-24 | 2006-04-06 | Trustees Of Dartmouth College | Chimeric nk receptor and methods for treating cancer |
| US9181527B2 (en) | 2009-10-29 | 2015-11-10 | The Trustees Of Dartmouth College | T cell receptor-deficient T cell compositions |
| US9273283B2 (en) | 2009-10-29 | 2016-03-01 | The Trustees Of Dartmouth College | Method of producing T cell receptor-deficient T cells expressing a chimeric receptor |
| SG190997A1 (en) | 2010-12-09 | 2013-07-31 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| WO2013033626A2 (en) | 2011-08-31 | 2013-03-07 | Trustees Of Dartmouth College | Nkp30 receptor targeted therapeutics |
| GB201201511D0 (en) * | 2012-01-30 | 2012-03-14 | Univ Leuven Kath | Modified epitopes for boosting CD4+ T-cell responses |
| US9790278B2 (en) | 2012-05-07 | 2017-10-17 | The Trustees Of Dartmouth College | Anti-B7-H6 antibody, fusion proteins, and methods of using the same |
| EP3730512A1 (en) * | 2012-07-13 | 2020-10-28 | The Trustees of the University of Pennsylvania | Enhancing activity of car t cells by co-introducing a bispecific antibody |
| WO2014055657A1 (en) | 2012-10-05 | 2014-04-10 | The Trustees Of The University Of Pennsylvania | Use of a trans-signaling approach in chimeric antigen receptors |
| US9573988B2 (en) | 2013-02-20 | 2017-02-21 | Novartis Ag | Effective targeting of primary human leukemia using anti-CD123 chimeric antigen receptor engineered T cells |
| PL2958943T3 (pl) | 2013-02-20 | 2020-04-30 | The Trustees Of The University Of Pennsylvania | Leczenie nowotworu złośliwego za pomocą humanizowanego chimerycznego receptora antygenowego anty-egfrviii |
| WO2014145252A2 (en) | 2013-03-15 | 2014-09-18 | Milone Michael C | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
| UY35468A (es) | 2013-03-16 | 2014-10-31 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19 |
| CN116478927A (zh) | 2013-12-19 | 2023-07-25 | 诺华股份有限公司 | 人间皮素嵌合抗原受体及其用途 |
| KR20230007559A (ko) * | 2013-12-20 | 2023-01-12 | 프레드 허친슨 캔서 센터 | 태그된 키메라 이펙터 분자 및 그의 리셉터 |
| WO2015090229A1 (en) | 2013-12-20 | 2015-06-25 | Novartis Ag | Regulatable chimeric antigen receptor |
| US11028143B2 (en) | 2014-01-21 | 2021-06-08 | Novartis Ag | Enhanced antigen presenting ability of RNA CAR T cells by co-introduction of costimulatory molecules |
| DK3129470T3 (da) | 2014-04-07 | 2021-07-05 | Novartis Ag | Behandling af cancer ved anvendelse af anti-CD19-kimær antigenreceptor |
| SG11201700418VA (en) | 2014-07-21 | 2017-02-27 | Novartis Ag | Treatment of cancer using a cll-1 chimeric antigen receptor |
| JP7054622B2 (ja) | 2014-07-21 | 2022-04-14 | ノバルティス アーゲー | ヒト化抗ｂｃｍａキメラ抗原受容体を使用した癌の処置 |
| BR112017001242A2 (pt) | 2014-07-21 | 2017-12-05 | Novartis Ag | tratamento de câncer usando um receptor antigênico quimérico a cd33 |
| WO2016014553A1 (en) | 2014-07-21 | 2016-01-28 | Novartis Ag | Sortase synthesized chimeric antigen receptors |
| SG11201700770PA (en) | 2014-08-19 | 2017-03-30 | Novartis Ag | Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment |
| PL3194443T3 (pl) | 2014-09-17 | 2022-01-31 | Novartis Ag | Nakierowywanie komórek cytotoksycznych za pośrednictwem receptorów chimerycznych do immunoterapii adoptywnej |
| KR102683584B1 (ko) * | 2014-09-19 | 2024-07-10 | 시티 오브 호프 | ＩＬ13Ｒα2를 표적화하는 공자극 키메라 항원 수용체 Ｔ 세포 |
| KR20170068504A (ko) | 2014-10-08 | 2017-06-19 | 노파르티스 아게 | 키메라 항원 수용체 요법에 대한 치료 반응성을 예측하는 바이오마커 및 그의 용도 |
| CA3197849A1 (en) | 2014-12-29 | 2016-07-07 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
| WO2016115482A1 (en) | 2015-01-16 | 2016-07-21 | Novartis Pharma Ag | Phosphoglycerate kinase 1 (pgk) promoters and methods of use for expressing chimeric antigen receptor |
| US11161907B2 (en) | 2015-02-02 | 2021-11-02 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
| HUE059218T2 (hu) | 2015-04-08 | 2022-11-28 | Novartis Ag | CD20-terápiák, CD22-terápiák és kombinációs terápiák CD19 kiméra antigénreceptort (CAR-t) expresszáló sejttel |
| CA2982996A1 (en) | 2015-04-17 | 2016-10-20 | David Maxwell Barrett | Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells |
| WO2017004252A1 (en) | 2015-06-30 | 2017-01-05 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Redirected cells with mhc chimeric receptors and methods of use in immunotherapy |
| JP7146632B2 (ja) | 2015-07-21 | 2022-10-04 | ノバルティス アーゲー | 免疫細胞の有効性および増大を改善する方法 |
| GB201513540D0 (en) * | 2015-07-31 | 2015-09-16 | King S College London | Therapeutic agents |
| WO2017027392A1 (en) | 2015-08-07 | 2017-02-16 | Novartis Ag | Treatment of cancer using chimeric cd3 receptor proteins |
| EP3344996A2 (en) | 2015-09-03 | 2018-07-11 | The Trustees Of The University Of Pennsylvania | Biomarkers predictive of cytokine release syndrome |
| EA201891338A1 (ru) | 2015-12-04 | 2018-12-28 | Новартис Аг | Композиции и способы для иммуноонкологии |
| CN109069597A (zh) | 2015-12-22 | 2018-12-21 | 诺华股份有限公司 | 间皮素嵌合抗原受体(car)和抗pd-l1抗体抑制剂联用于抗癌治疗 |
| TW202340473A (zh) | 2016-10-07 | 2023-10-16 | 瑞士商諾華公司 | 利用嵌合抗原受體之癌症治療 |
| ES2912408T3 (es) | 2017-01-26 | 2022-05-25 | Novartis Ag | Composiciones de CD28 y métodos para terapia con receptores quiméricos para antígenos |
| EP3601561A2 (en) | 2017-03-22 | 2020-02-05 | Novartis AG | Compositions and methods for immunooncology |
| AR123115A1 (es) | 2017-10-18 | 2022-11-02 | Novartis Ag | Composiciones y métodos para la degradación selectiva de proteínas |
| MX2020009272A (es) | 2018-03-06 | 2021-01-08 | Univ Pennsylvania | Receptores de antígeno quimérico del antígeno de membrana específico de próstata y métodos de uso de los mismos. |
| EP3806962A1 (en) | 2018-06-13 | 2021-04-21 | Novartis AG | Bcma chimeric antigen receptors and uses thereof |
| MX2022006365A (es) | 2019-11-26 | 2022-06-22 | Novartis Ag | Receptores de antigeno quimerico cd19 y cd22 y usos de los mismos. |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2074825C (en) * | 1990-12-14 | 2005-04-12 | Daniel J. Capon | Chimeric chains for receptor-associated signal transduction pathways |
| US5912170A (en) * | 1991-03-07 | 1999-06-15 | The General Hospital Corporation | Redirection of cellular immunity by protein-tyrosine kinase chimeras |
| NZ241855A (en) * | 1991-03-07 | 1994-04-27 | Gen Hospital Corp | Use of therapeutic cells to obtain cellular response to infection, tumours or autoimmune-generated cells, cells with chimaeric receptors (with binding component and destruction signal), dna encoding the receptor, vectors and antibodies to receptor |
| US5439819A (en) * | 1993-08-27 | 1995-08-08 | The Regents Of The University Of California | Chimeric protein tyrosine kinases |
-
1996
- 1996-01-25 AU AU48588/96A patent/AU708339B2/en not_active Expired
- 1996-01-25 JP JP52568596A patent/JP4170390B2/ja not_active Expired - Lifetime
- 1996-01-25 HU HU9801873A patent/HU225688B1/hu unknown
- 1996-01-25 CZ CZ19972599A patent/CZ295428B6/cs not_active IP Right Cessation
- 1996-01-25 RU RU97115769/14A patent/RU2167676C2/ru active
- 1996-01-25 ES ES96904498T patent/ES2245456T3/es not_active Expired - Lifetime
- 1996-01-25 WO PCT/US1996/001056 patent/WO1996025953A1/en active IP Right Grant
- 1996-01-25 NZ NZ337002A patent/NZ337002A/en not_active IP Right Cessation
- 1996-01-25 AT AT96904498T patent/ATE297986T1/de active
- 1996-01-25 KR KR1019970705850A patent/KR100490099B1/ko not_active IP Right Cessation
- 1996-01-25 CA CA2209300A patent/CA2209300C/en not_active Expired - Lifetime
- 1996-01-25 NZ NZ302513A patent/NZ302513A/xx not_active IP Right Cessation
- 1996-01-25 DE DE69634855T patent/DE69634855T2/de not_active Expired - Lifetime
- 1996-01-25 EP EP96904498A patent/EP0871495B1/en not_active Expired - Lifetime
- 1996-01-25 PT PT96904498T patent/PT871495E/pt unknown
- 1996-01-25 DK DK96904498T patent/DK0871495T3/da active
- 1996-02-23 ZA ZA9601477A patent/ZA961477B/xx unknown
-
1997
- 1997-08-21 FI FI973437A patent/FI119757B/fi not_active IP Right Cessation
- 1997-08-22 NO NO19973864A patent/NO323632B1/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2209300A1 (en) | 1996-08-29 |
| CZ295428B6 (cs) | 2005-08-17 |
| AU4858896A (en) | 1996-09-11 |
| ZA961477B (en) | 1997-02-03 |
| DE69634855D1 (de) | 2005-07-21 |
| JPH11505409A (ja) | 1999-05-21 |
| ES2245456T3 (es) | 2006-01-01 |
| AU708339B2 (en) | 1999-08-05 |
| EP0871495B1 (en) | 2005-06-15 |
| ATE297986T1 (de) | 2005-07-15 |
| KR19980702450A (ko) | 1998-07-15 |
| HUP9801873A2 (hu) | 1998-11-30 |
| PT871495E (pt) | 2005-10-31 |
| EP0871495A4 (en) | 2000-09-13 |
| KR100490099B1 (ko) | 2005-11-28 |
| NZ337002A (en) | 2005-07-29 |
| DE69634855T2 (de) | 2006-05-18 |
| RU2167676C2 (ru) | 2001-05-27 |
| WO1996025953A1 (en) | 1996-08-29 |
| FI119757B (fi) | 2009-03-13 |
| NZ302513A (en) | 1999-11-29 |
| NO973864D0 (no) | 1997-08-22 |
| NO973864L (no) | 1997-10-22 |
| HUP9801873A3 (en) | 2000-08-28 |
| HU225688B1 (en) | 2007-06-28 |
| CA2209300C (en) | 2011-06-28 |
| JP4170390B2 (ja) | 2008-10-22 |
| DK0871495T3 (da) | 2005-10-17 |
| NO323632B1 (no) | 2007-06-18 |
| FI973437A0 (fi) | 1997-08-21 |
| EP0871495A1 (en) | 1998-10-21 |
| CZ259997A3 (cs) | 1998-05-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI973437A (fi) | Soluimmuniteetin uudelleenkohdistus reseptorikimeerien avulla | |
| FI973466A (fi) | Soluimmuniteetin suuntaaminen uudelleen proteiinityrosiinikinaasikimeerojen avulla | |
| ATE308888T1 (de) | Gezielte zell-lyse von hiv-infizierten zellen mit chimären cd4 rezeptortragenden zellen | |
| BR9205736A (pt) | Redireçao de imunidade celular por quimeras de receptores. | |
| NO960175L (no) | Redirigering av cellulær immunitet med reseptor-chimeras |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Patent granted |
Ref document number: 119757 Country of ref document: FI |
|
| MA | Patent expired |